AstraZeneca (AZN) said Friday that its late-stage trial of its therapy, Imfinzi, when combined with standard BCG induction and maintenance therapy, showed significantly improved disease-free survival in patients with high-risk non-muscle-invasive bladder cancer.

The company said the trial was not statistically powered to formally test overall survival but a descriptive analysis demonstrated no detriment.

The drugmaker said the therapy did not raise new safety concerns and did not compromise patients' ability to complete BCG induction and maintenance therapy.

A second experimental arm evaluating Imfinzi combined with BCG induction-only therapy compared to BCG induction and maintenance therapy alone failed to meet the endpoint of disease-free survival, the company said.